On November 30, 2018 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, reported presentations of clinical and scientific data related to Peripheral T-cell Lymphoma (PTCL) and EVOMELA (melphalan) at the 60th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) being held in San Diego, California, from December 1-4, 2018 (Press release, Spectrum Pharmaceuticals, NOV 30, 2018, View Source [SID1234531743]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information about the ASH (Free ASH Whitepaper) annual meeting and for a complete list of abstracts, please refer to the conference website at View Source

The following posters will be presented at the ASH (Free ASH Whitepaper) meeting:

Management of Mucositis with Use of Leucovorin as Adjunct to Pralatrexate in Treatment of Patients with Hematological Malignancies including of Peripheral and Cutaneous T-Cell Lymphomas-Results from a Prospective Multicenter Phase 2 Clinical Trial. Poster 2910; Presented on Sunday, Dec 2, 6:00 PM-8:00 PM, Hall GH
Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry. Poster 2926; Presented on Sunday, Dec 2, 6:00 PM-8:00 PM, Hall GH
Safety and Efficacy of Evomela in Myeloma Autotransplants; Poster 3446; Presented on Sunday, Dec 2, 6:00 PM-8:00 PM, Hall GH